CalciMedica reports Q2 2026 results, advances pulmonary hypertension and pancreatitis programs

CalciMedica reported financial results for the quarter ended June 30, 2026 alongside a set of clinical and corporate updates on August 11, 2026.

On the pulmonary hypertension side, the company announced on June 24, 2026 a private placement of up to approximately $49 million in gross proceeds, including about $15 million upfront, intended to support advancement of Auxora and CM5480 as part of its pulmonary hypertension strategy.¹ CalciMedica plans a Phase 1b proof-of-concept trial of Auxora in patients with pulmonary arterial hypertension to generate initial clinical evidence on CRAC channel inhibition, with data anticipated in mid-2027.¹ An IND submission for CM5480, its oral CRAC channel inhibitor candidate, is also anticipated in mid-2027.¹

In acute pancreatitis, following a Type C Focused Meeting on July 29, 2026, FDA aligned with the company's Phase 2b trial design for Auxora, with a primary endpoint measuring reduction in new-onset severe respiratory failure, key secondary endpoints of multi-organ failure and time to medically ready discharge, and an evaluation of elevated LDH as a risk marker.¹ Initiation of that trial is subject to additional financing.¹

Separately, the Journal of Clinical Investigation published a study on July 28, 2026 titled "The CRAC Channel Inhibitor Auxora Reprograms Pathogenic Alveolar Macrophage-T Cell Circuits in Viral Pneumonia."¹

On the KOURAGE trial in acute kidney injury with respiratory failure, enrollment was paused in January 2026 following a mortality imbalance, though no drug-related toxicity was identified; FDA reviewed a protocol amendment and interim safety data without comment, and the company does not plan to restart KOURAGE at this time.¹

On finances, cash and cash equivalents were $18.6 million as of June 30, 2026, which the company expects to fund its current operating plan into the second half of 2027.¹